Alliancebernstein L.P. decreased its stake in Seres Therapeutics, Inc. (NASDAQ:MCRB) by 5.2% during the first quarter, Holdings Channel reports. The institutional investor owned 32,600 shares of the biotechnology company’s stock after selling 1,800 shares during the period. Alliancebernstein L.P.’s holdings in Seres Therapeutics were worth $367,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of MCRB. American International Group Inc. boosted its stake in shares of Seres Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 727 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after buying an additional 50,860 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of Seres Therapeutics by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 21,335 shares of the biotechnology company’s stock valued at $240,000 after buying an additional 279 shares in the last quarter. American Century Companies Inc. acquired a new stake in shares of Seres Therapeutics during the first quarter valued at about $447,000. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Seres Therapeutics during the first quarter valued at about $136,000. 75.31% of the stock is currently owned by institutional investors and hedge funds.

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) traded up 2.30% during mid-day trading on Friday, reaching $13.77. 97,984 shares of the company traded hands. Seres Therapeutics, Inc. has a 52-week low of $8.85 and a 52-week high of $15.09. The company’s market capitalization is $557.85 million. The firm’s 50 day moving average price is $12.55 and its 200-day moving average price is $10.69.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.10. The firm had revenue of $3 million for the quarter, compared to analysts’ expectations of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.70) EPS. Equities analysts predict that Seres Therapeutics, Inc. will post ($2.48) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Alliancebernstein L.P. Lowers Stake in Seres Therapeutics, Inc. (MCRB)” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/alliancebernstein-l-p-lowers-stake-in-seres-therapeutics-inc-mcrb/1478853.html.

Several brokerages have recently issued reports on MCRB. BidaskClub raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research cut shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. ValuEngine raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Canaccord Genuity set a $20.00 price target on shares of Seres Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, HC Wainwright reissued a “buy” rating and set a $19.00 price target (up previously from $15.00) on shares of Seres Therapeutics in a research report on Friday, August 4th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Seres Therapeutics has a consensus rating of “Buy” and a consensus target price of $17.00.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Want to see what other hedge funds are holding MCRB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seres Therapeutics, Inc. (NASDAQ:MCRB).

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.